Welcome to our dedicated page for Candel Therapeutics news (Ticker: CADL), a resource for investors and traders seeking the latest updates and insights on Candel Therapeutics stock.
Candel Therapeutics, Inc. (NASDAQ: CADL) is a clinical-stage biopharmaceutical company pioneering viral immunotherapies for solid tumor treatment. This page serves as the definitive source for official updates on the company's innovative adenovirus and herpes simplex virus (HSV) platform developments.
Investors and researchers will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes press releases detailing therapy advancements, peer-reviewed research collaborations, and manufacturing updates relevant to CADL's immuno-oncology pipeline.
Key content categories include phase trial results, FDA communications, intellectual property developments, and executive leadership announcements. All materials are sourced directly from company filings and verified channels to ensure accuracy.
Bookmark this page for streamlined access to Candel Therapeutics' latest developments in cancer immunotherapy. Check regularly for updates on their gmci™ and rqnestin34.5 platforms as they progress through clinical evaluation.
Rhea-AI Summary
Candel Therapeutics, Inc. announces positive data from ongoing phase 1b clinical trial of CAN-3110 for rHGG patients, showing promising results in overall survival and tolerability. The company received FDA Fast Track Designation for CAN-3110 in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.76%
Tags
-
Rhea-AI Summary
Candel Therapeutics, Inc. reported financial results for Q4 2023, with positive clinical trial outcomes for CAN-2409 in pancreatic cancer and CAN-3110 in high-grade glioma. The company received FDA Fast Track Designations for both treatments, showing improved survival rates compared to standard care. Candel anticipates significant data readouts in 2024 across various cancer platforms, including a potentially registrational phase 3 trial for prostate cancer. Financially, research and development expenses increased due to activities supporting CAN-2409 programs, resulting in a net loss for Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.6%
Tags
-
Rhea-AI Summary
Candel Therapeutics, Inc. (CADL) will present a poster at the AACR Annual Meeting on a first-in-class immunotherapy candidate for solid tumors, accelerating the unveiling of the second enLIGHTEN™ program. The presentation focuses on inducing tertiary lymphoid structures as a novel therapeutic strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.07%
Tags
Rhea-AI Summary
Candel Therapeutics, Inc. (CADL) receives FDA Fast Track Designation for CAN-3110, a promising oncolytic viral immunotherapy candidate for recurrent high-grade glioma. Positive results from the phase 1b clinical trial show a nearly doubled median overall survival with a single injection, highlighting the therapy's potential to address the unmet needs in this therapy-resistant condition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.5%
Tags
-
Rhea-AI Summary
Candel Therapeutics, Inc. (Nasdaq: CADL) has highlighted upcoming milestones, including data readouts in lung, pancreatic, brain, and prostate cancer, as well as recent successes in immunotherapy. The company received Fast Track Designation from the FDA for its product candidate, CAN-2409, and reported positive clinical trial data for CAN-3110. These developments position Candel for progress and differentiation in the cancer therapeutics market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
-
Rhea-AI Summary
Candel Therapeutics, Inc. (Candel) (Nasdaq: CADL) has been granted Fast Track Designation by the FDA for its lead investigational adenovirus asset CAN-2409 plus prodrug for the treatment of pancreatic ductal adenocarcinoma (PDAC) to improve overall survival. The company presented encouraging overall survival and immunological biomarker data based on an interim analysis of the randomized, phase 2 clinical trial at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. The estimated survival rate of patients who received the CAN-2409 plus prodrug regimen was 71.4% at both 24 and 36 months, compared to only 16.7% in patients treated with standard of care (SoC) chemoradiation prior to surgery alone. Candel remains on track to release updated overall survival data in the second quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.23%
Tags
Rhea-AI Summary
Candel Therapeutics, Inc. (CADL) strategically restructures to focus on developing CAN-3110 and the enLIGHTEN™ Discovery Platform, reducing workforce by 50% to extend cash runway into Q4 2024. The company aims to prioritize spend on clinical data readouts for CAN-2409 in non-small cell lung cancer, pancreatic cancer, and prostate cancer in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.16%
Tags
-
News
Rhea-AI Summary
Candel Therapeutics, Inc. (CADL) reported positive survival data from phase 2 trials of CAN-2409 in NSCLC and pancreatic cancer, and CAN-3110 in recurrent HGG. The company also presented promising results for Alpha-201-macro1 and provided a corporate update on financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13%
Tags
-
Rhea-AI Summary
Candel Therapeutics presents two posters at the 2023 SITC Annual Meeting, showcasing the enLIGHTEN™ Discovery Platform. The platform combines artificial intelligence, machine learning, and herpes simplex virus to develop viral immunotherapies for solid tumors. The first poster highlights the potential of the enLIGHTEN™ viral chassis Alpha-201 to orchestrate changes in the tumor microenvironment and enhance anti-tumor immune responses. The second poster introduces Alpha-201-macro1, an investigational agent designed to interfere with the CD47/SIRPα pathway and demonstrate potent anti-tumor effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Candel Therapeutics announced positive interim data from a phase 2 clinical trial of CAN-2409 for pancreatic cancer. The overall survival rate at 36 months was 71.4% in CAN-2409 treated patients compared to 16.7% in the control arm. Immune response was observed in PDAC tissue after CAN-2409 treatment. The treatment was well tolerated with no dose-limiting toxicities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.51%
Tags
Candel Therapeutics, Inc.
Nasdaq:CADL
CADL Rankings
CADL Stock Data
215.87M
38.51M
18.54%
44.13%
7.5%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
NEEDHAM